Latest Breaking News On - Yasuhiro maeda - Page 1 : comparemela.com

Salix Pharmaceuticals: Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Salix Pharmaceuticals: Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-kingdom
New-jersey
United-states
Washington
American
British
Garen-sarafian
Yasuhiro-maeda
Kevin-wiggins
Kunio-sugahara
American-society-for-gastrointestinal-endoscopy
Linkedin

Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod ...

Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod ...
pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.

United-states
New-jersey
United-kingdom
Washington
British
American
Kunio-sugahara
Garen-sarafian-kevin
Yasuhiro-maeda
Salix-pharmaceuticals
News-network
Society-for-surgery-of-the-alimentary-tract

Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.

United-states
Washington
United-kingdom
New-jersey
American
British
Yasuhiro-maeda
Kunio-sugahara
Salix-pharmaceuticals
Bausch-health-companies-inc
Linkedin
American-gastroenterological-association

Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis

Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis
torontotelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from torontotelegraph.com Daily Mail and Mail on Sunday newspapers.

United-kingdom
Canada
Canadian
British
Thomasj-appio
Kevin-wiggins
Kunio-sugahara
Lisa-wilson
Yasuhiro-maeda
Linkedin
Pharmacological-research
Lomb-corporation

Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis

Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Canada
United-kingdom
Canadian
British
Kunio-sugahara
Yasuhiro-maeda
Lisa-wilson
Kevin-wiggins
Thomasj-appio
Bausch-health
Pharmacological-research
Bausch-health-phase